Healthcare provider profile · identity verified

Raymond Dormevil, M.D

Family Practice · BROOKLYN, NY · NPI 1245627892

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	858	303
Amlodipine Besylate	Amlodipine Besylate	686	228
Losartan Potassium	Losartan Potassium	371	126
Lisinopril	Lisinopril	241	78
Glipizide	Glipizide	235	84
Gabapentin	Gabapentin	231	84
Metformin Hcl	Metformin Hcl	228	76
Metformin Hcl Er	Metformin Hcl	186	61
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	185	65
Hydrochlorothiazide	Hydrochlorothiazide	177	62
Arexvy	Rsvpref3 Antigen/As01e/Pf	175	175
Furosemide	Furosemide	172	68
Jardiance	Empagliflozin	150	53
Albuterol Sulfate Hfa	Albuterol Sulfate	140	54
Famotidine	Famotidine	139	55
Oxycodone Hcl	Oxycodone Hcl	133	25
Tamsulosin Hcl	Tamsulosin Hcl	131	52
Pantoprazole Sodium	Pantoprazole Sodium	127	42
Metoprolol Tartrate	Metoprolol Tartrate	118	47
Levothyroxine Sodium	Levothyroxine Sodium	113	39
Carvedilol	Carvedilol	110	33
Allopurinol	Allopurinol	99	35
Pradaxa	Dabigatran Etexilate Mesylate	98	35
Hydralazine Hcl	Hydralazine Hcl	87	37
Simvastatin	Simvastatin	85	25
Ibuprofen	Ibuprofen	78	34
Tramadol Hcl	Tramadol Hcl	77	17
Trazodone Hcl	Trazodone Hcl	72	20
Ciclopirox	Ciclopirox Olamine	70	48
Pravastatin Sodium	Pravastatin Sodium	66	21
Atenolol	Atenolol	65	22
Spironolactone	Spironolactone	65	27
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	64	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	64	21
Shingrix	Varicella-Zoster Ge/As01b/Pf	63	59
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	63	23
Wixela Inhub	Fluticasone Propion/Salmeterol	61	13
Prednisone	Prednisone	55	35
Metoprolol Succinate	Metoprolol Succinate	54	24
Triamcinolone Acetonide	Triamcinolone Acetonide	54	41
Ozempic	Semaglutide	52	suppressed
Potassium Chloride	Potassium Chloride	52	23
Duloxetine Hcl	Duloxetine Hcl	51	17
Pregabalin	Pregabalin	50	17
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	45	suppressed
Sertraline Hcl	Sertraline Hcl	44	16
Clonidine Hcl	Clonidine Hcl	42	suppressed
Humulin N	Insulin Nph Human Isophane	42	12
Rosuvastatin Calcium	Rosuvastatin Calcium	41	16
Meloxicam	Meloxicam	39	22
Clopidogrel	Clopidogrel Bisulfate	38	13
Trospium Chloride	Trospium Chloride	38	13
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	37	11
Acyclovir	Acyclovir	35	suppressed
Montelukast Sodium	Montelukast Sodium	35	13
Nifedipine Er	Nifedipine	34	suppressed
Humalog Kwikpen U-100	Insulin Lispro	33	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	32	suppressed
Hydrocortisone	Hydrocortisone	31	27
Mirtazapine	Mirtazapine	31	14
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	31	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	30	11
Alvesco	Ciclesonide	30	16
Eliquis	Apixaban	30	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	28	28
Clobetasol Propionate	Clobetasol Propionate	28	15
Ondansetron Odt	Ondansetron	27	11
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	26	suppressed
Azelastine Hcl	Azelastine Hcl	25	16
Humulin N Kwikpen	Insulin Nph Human Isophane	25	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	25	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	23	21
Chlorthalidone	Chlorthalidone	22	suppressed
Naproxen	Naproxen	22	suppressed
Sucralfate	Sucralfate	22	suppressed
Alendronate Sodium	Alendronate Sodium	21	suppressed
Terazosin Hcl	Terazosin Hcl	21	suppressed
Colchicine	Colchicine	20	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	20	suppressed
Entresto	Sacubitril/Valsartan	20	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	20	suppressed
Finasteride	Finasteride	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	14
Lamotrigine	Lamotrigine	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	19	suppressed
Alprazolam	Alprazolam	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Latanoprost	Latanoprost	17	suppressed
Sure Comfort Pen Needle	Pen Needle, Diabetic	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	11
Glipizide Er	Glipizide	15	suppressed
Omeprazole	Omeprazole	15	suppressed
Labetalol Hcl	Labetalol Hcl	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Lactulose	Lactulose	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Guanfacine Hcl Er	Guanfacine Hcl	12	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Liraglutide	Liraglutide	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Topiramate	Topiramate	12	suppressed
Valsartan	Valsartan	12	suppressed
Victoza 2-Pak	Liraglutide	12	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	11	suppressed
Cilostazol	Cilostazol	11	suppressed
Fluticasone Propionate	Fluticasone Propionate	11	suppressed
Methimazole	Methimazole	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error